medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2015, Number 2

<< Back Next >>

Rev Esp Med Quir 2015; 20 (2)

Treatment of pediatric imperfect osteogenesis with zoledronic acid

Espíndola-Corres JA, Colín-Martínez Ó, Delgado-Pérez JA, Isunza-Ramírez A

Language: Spanish
References: 12
Page: 178-183
PDF size: 813.19 Kb.


ABSTRACT

Imperfect osteogenesis is a hereditary pathology showing abnormal qualitative and quantitative production of collagen. Mutation in one of two genes that encode the chains of collagen type I (COL1A1 and COL1A2) is observed in 70% of patients, affecting different tissues. This disease is characterized by bone fragility with a variable clinical spectrum including few fractures or severe skeletal deformities. The introduction of bisphosphonates treatment in the last decade has demonstrated to decrease fracture rate, relief pain, and improve functional status and quality of life of the patients.


REFERENCES

  1. Carrie A. P. Remmington T. Steiner R. D. Tratamiento con Bifosfonatos para la osteogenesis Imperfecta. Biblioteca Cochrane Plus, Agosto 2008, Número 4. Numero Cochrane Library CD005088.

  2. Ruck J. Dahan-Oliel D. Montpetit K. Rauch F. Fassier F. Fassier–Duval femoral roddingin children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop 2011;5:217-224.

  3. Chiasson R.M. Munns C. Zeitlin L. Enfoque interdiciplinario para el tratamiento de la osteogénesis imperfecta en niños, Hospital Shriners para Niños, Montreal, Quebec, Canadá pag. 14 -21, 2004.

  4. Matos MA. Araujo FP. Paixao FB. The effect of zoledronate on bone remodeling during the healing process, Acta Cirúrgica Brasileira 2007;22(2):115-119.

  5. Matos MA. Tannuri U. Guarniero R. The effect of zoledronate during bone healing, J Orthopaed Traumatol 2010;11:7-12.

  6. Anurag B. MD, Madhulika, MD. Intravenous Pamidronate Therapy in Osteogenesis Imperfecta Response to Treatment and Factors Influencing Outcome. J Pediatr Orthop & Volume 27, Number 2, March 2007.

  7. Glorieux FH, Rauch F. Osteogenesis imperfecta. The Lancet 2004;363(9418):1377-85.

  8. Glorieux FH. Cyclic administration of pamidronate therapy in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.

  9. Glorieux H.F., Fassier F., Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate. J Bone Miner Res 2004;19:1779-1786.

  10. Hernández H. J,L. Riancho M. J.A. González M. J. Bisfosfonatos intravenosos. Med Clin (Barc) 2005;124(9):348-54.

  11. Lozada O. H Solaque. Terapia con bifosfonatos en osteogenesis imperfect, Rev Col de Ort y Traum, Vol 23 No 2 junio 2009. 109-114.

  12. Astrom E. Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356-364.




2020     |     www.medigraphic.com